Back to search

National and Kapodistrian University of Athens

Λιποκίνες, κυτταροκίνες και δείκτες ινσουλινοαντίστασης σε γυναίκες με μετεμμηνοπαυσιακό καρκίνο του μαστού

Abstract

dc:description

Introduction: Dysregulation of adipokines, hormones secreted from adipose tissue, has been reported in various solid tumors, including postmenopausal breast cancer (PBC). While classic adipokines, such as leptin and adiponectin, have been associated with BC in many studies, little is known about novel adipokines.Aim: The aim of the present doctoral thesis was to investigate the association of classic adipokines, especially the newly discovered omentin-1, which is an anti-inflammatory and proapoptotic adipokine, with PBC taking into consideration clinicopathologic features, inflammatory parameters, biomarkers of insulin resistance, tumor markers, anthropometric, dietary and cardiometabolic parameters as well as their diagnostic potential.Materials and methods: In this case-control study serum leptin, adiponectin and omentin-1, inflammatory parameters (TNFa, IL-6 and hsCRP), biomarkers of insulin resistance (insulin, HOMA-IR index, presence and grade of metabolic syndrome), tumor markers (CA15-3 and CEA), metabolic (glucose and serum lipids), anthropometric (BMI, waist circumference and fat mass), blood pressure (systolic, diastolic and mean BP) parameters, the Mediterranean diet (MedDiet) score, and cardiovascular risk (Framingham risk score) were determined in 103 postmenopausal women with pathologically confirmed incident invasive BC who had not received any type of therapy, 103 controls matched on age and time to the diagnosis, 51 patients with benign breast lesions (BBL), and 50 obese postmenopausal women without any kind of malignancy of similar age.Results: The mean serum leptin of cases with PBC was similar to the corresponding levels of controls (p=0.7) or women with BBL (p=0.6), but was significantly lower than in participants with obesity (p<0.001). The mean serum adiponectin was significantly lower in cases than in controls (p=0.04) and was similar to the corresponding levels of women with BBL (p=0.30) or participants with obesity (p=0.44). The mean serum omentin-1 was significantly lower in cases than in controls or women with BBL (p<0.001), but was similar to the corresponding levels of participants with obesity (p=0.21). In cases with PBC, omentin-1 was inversely associated with anthropometric, tumor, metabolic and inflammatory biomarkers, cancer stage, and the number of infiltrated lymph nodes (p<0.05). In all study participants, circulating omentin-1 was negatively correlated with cardiometabolic risk factors, such as Framingham risk score, and was positively correlated with MedDiet score and HDL-C. Cases with PBC, tended to present a more frequent history and a higher grade of metabolic syndrome than in controls, but a less frequent history and a similar grade of metabolic syndrome than in participants with obesity. Lower circulating omentin-1 was independently associated with PBC occurrence above and beyond known risk factors, as well as metabolic and inflammatory parameters. According to the ROC curve analysis, the overall diagnostic performance of omentin-1 was similar to that of CA15-3 in PBC diagnosis, but with a poorer discriminative ability in postmenopausal women with obesity. Additionally, the diagnostic performance of omentin-1 was better than the diagnostic performance of CEA, adiponectin and leptin in the diagnosis of PBC.Conclusions: Serum omentin-1 may be a biomarker at the intersection of PBC and cardiometabolic risk in postmenopausal women. Circulating omentin-1 could be modulated by the adoption of the anti-inflammatory and antioxidant MedDiet. Low circulating omentin-1 may signal lymph node invasion, negative hormonal receptor status and increased cardiometabolic risk in postmenopausal women with BC. However, further mechanistic and large multicentric prospective and longitudinal studies are required to elucidate the ontological role of the newly discovered omentin-1 in BC and CVD risks, as well as its diagnostic and prognostic ability and its therapeutic potential.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Christodoulatos, Gerasimos-Socrates
  • Χριστοδουλάτος, Γεράσιμος-Σωκράτης

Subjects

dc:subject × 22

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/51875

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Christodoulatos, Gerasimos-Socrates; Χριστοδουλάτος, Γεράσιμος-Σωκράτης. Λιποκίνες, κυτταροκίνες και δείκτες ινσουλινοαντίστασης σε γυναίκες με μετεμμηνοπαυσιακό καρκίνο του μαστού. National and Kapodistrian University of Athens, 2022. http://hdl.handle.net/10442/hedi/51875